Durvalumab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis
- Status
- WITHDRAWN
- Phase
- PHASE1
Clinical Trials Related to Durvalumab
Related studies linked through entity extraction aliases.
Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care in Patients With Advanced Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE2
A Study Evaluating the Association of Hypofractionated Stereotactic Radiation Therapy and Durvalumab for Patients With Recurrent Glioblastoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer
- Status
- TERMINATED
- Phase
- EARLY_PHASE1
Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)
- Status
- COMPLETED
- Phase
- PHASE2
Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes
- Status
- COMPLETED
- Phase
- PHASE2
Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- EARLY_PHASE1
Study of Azacitidine and Durvalumab in Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE2
A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE2
Abrogation of Chronic Monoclonal Antibody Treatment-induced T-cell Exhaustion With DURVALUMAB in Advanced HER-2 Negative Breast Cancer
- Status
- COMPLETED
- Phase
- EARLY_PHASE1
Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma
- Status
- COMPLETED
- Phase
- PHASE2
Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers
- Status
- COMPLETED
- Phase
- PHASE1
An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML)
- Status
- COMPLETED
- Phase
- PHASE2
Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3
TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma
- Status
- COMPLETED
- Phase
- PHASE1
Tremelimumab and Durvalumab in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery
- Status
- COMPLETED
- Phase
- PHASE1
A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies
- Status
- COMPLETED
- Phase
- PHASE1